{"id":8816,"date":"2026-01-29T17:41:20","date_gmt":"2026-01-29T17:41:20","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8816"},"modified":"2026-01-29T17:41:20","modified_gmt":"2026-01-29T17:41:20","slug":"serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","title":{"rendered":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment<\/em><\/h4>\n\n\n\n<p>Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to move forward with regulatory preparations and clinical site activities supporting an upcoming Phase 1b registrational study.<\/p>\n\n\n\n<p>The IND, or Investigational New Drug, clearance marks a critical step in bringing SER-252 closer to patients suffering from advanced Parkinson\u2019s disease, a condition where treatment options remain limited and symptom management becomes increasingly challenging over time. With approval in hand, Serina can now begin patient-focused clinical efforts designed to evaluate the therapy\u2019s safety and potential benefits in real-world clinical settings.<\/p>\n\n\n\n<p>Company leadership described the development as a pivotal moment for the program, emphasizing that regulatory alignment with the FDA helps streamline the path toward eventual approval. The planned clinical program is structured under a 505(b)(2) regulatory pathway, which allows developers to leverage existing data on approved therapies while demonstrating improvements or advantages of a new treatment candidate. This approach can shorten development timelines and reduce overall risk compared with traditional drug approval pathways.<\/p>\n\n\n\n<p>In parallel, Serina has begun preparing international clinical infrastructure, including regulatory and site startup activities in Australia, to support what it describes as a global registrational strategy for SER-252.<\/p>\n\n\n\n<p>Investor enthusiasm followed the announcement, with shares of the company seeing a strong move higher as markets responded to progress in the pipeline. For patients and clinicians, however, the news signals something more important: continued advancement toward potential new treatment options in a disease area where medical innovation remains urgently needed.<\/p>\n\n\n\n<p>As clinical trials begin, the next phase of development will focus on generating data that could ultimately determine whether SER-252 becomes a meaningful addition to Parkinson\u2019s disease therapy in the years ahead.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/nikes-path-back-to-100-why-the-bull-case-is-regaining-momentum\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Nike\u2019s Path Back to $100: Why the Bull Case Is Regaining Momentum<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,359],"tags":[451,421,416,418,901,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8816"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816\/revisions"}],"predecessor-version":[{"id":8817,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816\/revisions\/8817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8816"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}